Earnings Call · Q4 FY2021·2021-09-24

Q4 21EPS -20.59%·Rev n/aQ3 21EPS -34.43%·Rev n/aQ2 21EPS -20.52%·Rev n/aQ1 21EPS +97.94%·Rev n/a⚠ consensus missing

InMed Pharmaceuticals Inc. INM

Colin Clancy — Senior Director of Investor Relations

Eric Adams — President and CEO

Bruce Colwill — Chief Financial Officer (inferred from discussing fiscal year results and financial disclosures)

+0.5%1d on move date+0.8% vs SPY3d0.0%5d−6.6%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INM calls or request research access.

More INM calls Browse calls Request research access